New Findings See Cancer-Causing Carcinogens Increasing in our Medication
Scary thought. We rely on our doctors to recommend the right medication for our ailments. We rely on the FDA to ensure the safety of our medication. However, new evidence suggests that drugs can change and produce N-nitrosodimethylamine, NDMA, a probable carcinogen despite safety measures. Drugs previously thought safe are now being linked to cancer. […]
Drug Companies Investigated For Failing To Disclose Zantac Risks
At Colson Hicks Eidson, we have regularly discussed the cancer risks posed by Zantac and other generic forms of ranitidine. Over the last year, these medications have been recalled, and major companies have pulled them from their shelves. Now, federal investigators are looking into whether two drugmakers may have known about a probable carcinogen in […]
Months After Zantac Recalls, Ranitidine Lawsuits Move Forward
The makers of Zantac are potentially facing thousands of lawsuits due to cases related to their product containing a cancer-causing carcinogen. We have previously mentioned that federal judges approved transferring 15 Zantac-related cases to a South Florida court. Here, the award-winning team at Colson Hicks Eidson wants to discuss how many more potential lawsuits Zantac […]
